Economy/Home · Economy

[Breaking] Baropharm Shares Fall 13% on First Day of KOSDAQ Listing... Growth of Pharmacy Order Aggregation Platform Is Key

Baropharm, operator of a pharmaceutical order aggregation platform, listed on the KOSDAQ market on the 11th. The offering price was 16,400 won, with Mirae Asset Securities as the lead underwriter. The stock has been volatile on its first day of trading. As of 9:01 a.m. on the 11th, the share price

Wooil Shim
Staff Reporter
11 min read
[Breaking] Baropharm Shares Fall 13% on First Day of KOSDAQ Listing... Growth of Pharmacy Order Aggregation Platform Is Key
CBC News

Baropharm, operator of a pharmaceutical order aggregation platform, listed on the KOSDAQ market on the 11th. The offering price was 16,400 won, with Mirae Asset Securities as the lead underwriter.

The stock has been volatile on its first day of trading. As of 9:01 a.m. on the 11th, the share price stood at 14,140 won, down 13.78% from the offering price. The stock continues to fluctuate between gains and losses, so investors should remain mindful of volatility.

■ Order Aggregation Service Connecting Pharmacies Nationwide

Baropharm is expanding into pharmaceutical distribution and e-commerce based on an order aggregation service that connects pharmacies across the country. In particular, its business model combining marketplace-style e-commerce with pharmacies' existing ordering environment has emerged as a key point of interest in evaluating the company's value after listing.

Baropharm's order aggregation service allows pharmacies to search and order products from multiple pharmaceutical wholesalers on a single screen. It reduces the hassle of placing separate orders with each supplier and enables comparison of products from existing suppliers alongside those from new vendors.

■ Core Business 'Baropharm Mall'

One of the company's core businesses is the marketplace-style e-commerce service 'Baropharm Mall.' It is designed so pharmacies can purchase products from various suppliers directly on the ordering screen they use every day, without visiting separate shopping sites.

Unlike existing pharmaceutical wholesalers' online malls, which mainly operate around their own product lines, Baropharm Mall allows products from multiple vendors to be compared in the same search environment. Its product range has also expanded from prescription drugs to over-the-counter drugs, quasi-drugs, and cosmetics. The company is broadening its product categories into health supplements and beauty and cosmeceutical products, a strategy aimed at consolidating pharmacies' purchasing demand onto a single platform.

Baropharm explained that through its platform, products from participating vendors can be exposed on an ordering screen used by more than 90% of pharmacies nationwide. It presented as a competitive strength the ability to secure nationwide sales touchpoints without a separate large-scale pharmacy sales network. In particular, the structure provides a new sales channel beyond existing distribution networks for small and mid-sized pharmaceutical companies and new brands that lack their own sales networks.

■ Commission-Based Revenue Model... Growing Share of Transaction Volume

The revenue model also draws attention. The company receives brokerage commissions on Baropharm Mall transactions according to vendor contracts. The order aggregation service gathers pharmacies' ordering demand, and Baropharm Mall converts it into actual transactions. The structure is such that as pharmacies using the existing order aggregation service expand their purchases of Baropharm Mall products, transaction volume and commission revenue can grow together.

Indeed, the ratio of Baropharm Mall transaction volume (GMV) to total transaction volume (TGMV) rose from 11.9% in 2023 to 16.9% in 2025, meaning marketplace-style e-commerce is taking up a growing share of platform transactions.

However, an increase in transaction volume does not immediately translate into revenue or operating profit growth of the same scale. Actual profitability may vary depending on brokerage commission rates, operating costs, and the composition of traded products.

Prescription drugs are a key product category forming the foundation of platform transactions, as pharmacies continuously purchase them under prescriptions. Baropharm is expanding its business scope as a platform supplying a wide range of pharmacy products, including prescription drugs.

■ From Listing Schedule to Future Checkpoints

Listing preparations have been completed. Baropharm filed for a preliminary listing review on April 30 and received approval on August 12, submitted its securities report on September 8, and conducted demand forecasting from October 22 to 28. It began trading on the KOSDAQ market on the 11th, subjecting itself to market evaluation.

The key issue after listing is how well the existing order aggregation service's user base connects to increased Baropharm Mall transactions. The share of Baropharm Mall in transaction volume, brokerage commission revenue, and profitability changes from product category expansion are expected to be the main checkpoints.

However, the high usage rate of the pharmacy ordering network does not guarantee Baropharm Mall's actual purchase rates or profitability. The stock price in the early listing period may also fluctuate independently of the offering price depending on floating shares, investment demand, and market conditions.

Baropharm's KOSDAQ debut is expected to serve as an opportunity to see how the market evaluates a business model that combines an order aggregation platform with marketplace-style e-commerce in the pharmaceutical distribution sector.

[Some AI assistance was used in producing this article. This article does not recommend buying or selling any specific stock; investment decisions and responsibility rest with the investor.]

Wooil Shim
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.